Johnson & Johnson (JNJ), 2024 Q4 earnings digest

from Earnings Report Digest · host ValueVerge

$JNJ has released its Q4 2024 earnings report, showcasing a solid operational growth of 6.7% in worldwide sales, reaching $22.5B, driven by robust performance in Innovative Medicine and MedTech sectors. Key highlights include a notable 23.5% growth in DARZALEX sales. However, risks loom as Stelar’s growth is hindered by biosimilar competition. Future outlook suggests a steady 3% operational sales growth in 2025 with an anticipated 9% EPS increase.

Episode metadata supplied by the publisher feed · Published Jan 23, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

Johnson & Johnson (JNJ), 2024 Q4 earnings digest

0:00 1:45

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Earnings Report Digest?

This episode is 1 minute long.

When was this Earnings Report Digest episode published?

This episode was published on January 23, 2025.

Can I download this Earnings Report Digest episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!